{"id":{"repo_id":"temple","oai_identifier":"oai:scholarshare.temple.edu:20.500.12613/3791"},"canonical_url":"https://search.dev.ndltd.org/etd/temple/oai:scholarshare.temple.edu:20.500.12613/3791","repository":{"repo_id":"temple","name":"Temple University","base_url":"https://scholarshare.temple.edu/server/oai/request"},"display":{"title":"ABSENCE OF V1AR ALTERS CARDIAC FUNCTION AT BASELINE AND FOLLOWING ACUTE CARDIAC INJURY","abstract":"Heart failure (HF) is a prevalent disease affecting over 5.1 million people in the United States and over 23 million people worldwide. Many of the symptoms associated with HF are associated with neurohormonal responses to the decrease in cardiac output and systemic blood pressure, such as the activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. Current treatment guidelines recommend using drugs that block β-adrenergic receptor (βAR) signaling (e.g. β- blockers) or RAAS signaling (e.g. angiotensin receptor blockers/ARBs or angiotensin converting enzyme inhibitors/ACEi’s) Additionally, clinical studies have demonstrated that drugs blocking these neurohormones from properly signaling have decreased hospitalizations, morbidity, and mortality in these HF patients; and these are the only classes of pharmacological therapies that have been shown to reduce patient mortality. Interestingly, the neurohormone arginine vasopressin (AVP) has been implica","abstract_html":"Heart failure (HF) is a prevalent disease affecting over 5.1 million people in the United States and over 23 million people worldwide. Many of the symptoms associated with HF are associated with neurohormonal responses to the decrease in cardiac output and systemic blood pressure, such as the activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. Current treatment guidelines recommend using drugs that block β-adrenergic receptor (βAR) signaling (e.g. β- blockers) or RAAS signaling (e.g. angiotensin receptor blockers/ARBs or angiotensin converting enzyme inhibitors/ACEi’s) Additionally, clinical studies have demonstrated that drugs blocking these neurohormones from properly signaling have decreased hospitalizations, morbidity, and mortality in these HF patients; and these are the only classes of pharmacological therapies that have been shown to reduce patient mortality. Interestingly, the neurohormone arginine vasopressin (AVP) has been implica","abstract_has_math":false,"creators":["Wasilewski, Melissa Anne"],"institution":"Temple University. Libraries","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Tilley, Douglas G."],"committee_chairs":[],"committee_members":["Koch, Walter J.","Elrod, John W.","Feldman, Arthur M. (Arthur Michael), 1949-","Cheung, Joseph"],"year":2018,"date_issued":"2018","date_published":"2018","updated_at":"2026-07-27T21:20:27Z","subjects":["Biology, Molecular","Cellular biology"],"languages":["eng"],"rights":["IN COPYRIGHT- This Rights Statement can be used for an Item that is in copyright. Using this statement implies that the organization making this Item available has determined that the Item is in copyright and either is the rights-holder, has obtained permission from the rights-holder(s) to make their Work(s) available, or makes the Item available under an exception or limitation to copyright (including Fair Use) that entitles it to make the Item available."],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/20.500.12613/3791","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Tilley, Douglas G."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Koch, Walter J.","Elrod, John W.","Feldman, Arthur M. (Arthur Michael), 1949-","Cheung, Joseph"]},{"key":"dc:creator","label":"Author","values":["Wasilewski, Melissa Anne"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2020-11-05T16:10:01Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2020-11-05T16:10:01Z"]},{"key":"dc:date.issued","label":"Date","values":["2018"]},{"key":"dc:publisher","label":"Institution","values":["Temple University. Libraries"]},{"key":"dc:type","label":"Dc Type","values":["Text"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biology, Molecular","Cellular biology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["IN COPYRIGHT- This Rights Statement can be used for an Item that is in copyright. Using this statement implies that the organization making this Item available has determined that the Item is in copyright and either is the rights-holder, has obtained permission from the rights-holder(s) to make their Work(s) available, or makes the Item available under an exception or limitation to copyright (including Fair Use) that entitles it to make the Item available."]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/20.500.12613/3791"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Heart failure (HF) is a prevalent disease affecting over 5.1 million people in the United States and over 23 million people worldwide. Many of the symptoms associated with HF are associated with neurohormonal responses to the decrease in cardiac output and systemic blood pressure, such as the activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. Current treatment guidelines recommend using drugs that block β-adrenergic receptor (βAR) signaling (e.g. β- blockers) or RAAS signaling (e.g. angiotensin receptor blockers/ARBs or angiotensin converting enzyme inhibitors/ACEi’s) Additionally, clinical studies have demonstrated that drugs blocking these neurohormones from properly signaling have decreased hospitalizations, morbidity, and mortality in these HF patients; and these are the only classes of pharmacological therapies that have been shown to reduce patient mortality. Interestingly, the neurohormone arginine vasopressin (AVP) has been implica"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Ph.D."]},{"key":"dc:title","label":"Title","values":["ABSENCE OF V1AR ALTERS CARDIAC FUNCTION AT BASELINE AND FOLLOWING ACUTE CARDIAC INJURY"]}]}],"canonical_facts":{"dc:contributor.advisor":["Tilley, Douglas G."],"dc:contributor.committeemember":["Koch, Walter J.","Elrod, John W.","Feldman, Arthur M. (Arthur Michael), 1949-","Cheung, Joseph"],"dc:creator":["Wasilewski, Melissa Anne"],"dc:date.accessioned":["2020-11-05T16:10:01Z"],"dc:date.available":["2020-11-05T16:10:01Z"],"dc:date.issued":["2018"],"dc:description.abstract":["Heart failure (HF) is a prevalent disease affecting over 5.1 million people in the United States and over 23 million people worldwide. Many of the symptoms associated with HF are associated with neurohormonal responses to the decrease in cardiac output and systemic blood pressure, such as the activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. Current treatment guidelines recommend using drugs that block β-adrenergic receptor (βAR) signaling (e.g. β- blockers) or RAAS signaling (e.g. angiotensin receptor blockers/ARBs or angiotensin converting enzyme inhibitors/ACEi’s) Additionally, clinical studies have demonstrated that drugs blocking these neurohormones from properly signaling have decreased hospitalizations, morbidity, and mortality in these HF patients; and these are the only classes of pharmacological therapies that have been shown to reduce patient mortality. Interestingly, the neurohormone arginine vasopressin (AVP) has been implica"],"dc:description.degree":["Ph.D."],"dc:identifier.uri":["http://hdl.handle.net/20.500.12613/3791"],"dc:language.iso":["eng"],"dc:publisher":["Temple University. Libraries"],"dc:rights":["IN COPYRIGHT- This Rights Statement can be used for an Item that is in copyright. Using this statement implies that the organization making this Item available has determined that the Item is in copyright and either is the rights-holder, has obtained permission from the rights-holder(s) to make their Work(s) available, or makes the Item available under an exception or limitation to copyright (including Fair Use) that entitles it to make the Item available."],"dc:rights.uri":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:subject":["Biology, Molecular","Cellular biology"],"dc:title":["ABSENCE OF V1AR ALTERS CARDIAC FUNCTION AT BASELINE AND FOLLOWING ACUTE CARDIAC INJURY"],"dc:type":["Text"]},"updated_at":"2026-07-27T21:20:27Z"}